| pubmed-article:6546688 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6546688 | lifeskim:mentions | umls-concept:C0027819 | lld:lifeskim |
| pubmed-article:6546688 | lifeskim:mentions | umls-concept:C0017638 | lld:lifeskim |
| pubmed-article:6546688 | lifeskim:mentions | umls-concept:C0205145 | lld:lifeskim |
| pubmed-article:6546688 | lifeskim:mentions | umls-concept:C0682527 | lld:lifeskim |
| pubmed-article:6546688 | lifeskim:mentions | umls-concept:C0031978 | lld:lifeskim |
| pubmed-article:6546688 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
| pubmed-article:6546688 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:6546688 | pubmed:dateCreated | 1984-4-26 | lld:pubmed |
| pubmed-article:6546688 | pubmed:abstractText | The specific binding of both the non-classical antagonist [3H] pirenzepine ( [3H]PZ) and the classical antagonist [3H](-)quinuclidinyl benzilate ( [3H](-)QNB) was determined in parallel assays of the mouse neuroblastoma x rat glioma hybrid cell line (NG 108-15). Saturation isotherms yielded a Kd = 4.0 nM and Bmax = 27.8 fmoles/mg protein for [3H]PZ and a Kd = 17.2 pM and Bmax = 53.2 fmoles/mg protein for [3H](-)QNB. The inhibition data of pirenzepine vs [3H](-)QNB was best fit to a 2-site binding model revealing both a high affinity pirenzepine site (72%, KH = 10.3 nM) and a low affinity site (28%, KL = 97.5 nM). [3H]PZ competition studies demonstrated stereospecificity, steep inhibition curves for muscarinic antagonists (Hill coefficients close to 1), and a shallow inhibition curve for a muscarinic agonist. These results indicate that muscarinic receptors on NG 108-15 cells may be subclassified (M1/M2) on the basis of the discriminative capability of [3H]PZ. | lld:pubmed |
| pubmed-article:6546688 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6546688 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6546688 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6546688 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6546688 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6546688 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6546688 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6546688 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6546688 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6546688 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6546688 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6546688 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6546688 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:6546688 | pubmed:issn | 0006-291X | lld:pubmed |
| pubmed-article:6546688 | pubmed:author | pubmed-author:YamamuraH IHI | lld:pubmed |
| pubmed-article:6546688 | pubmed:author | pubmed-author:AkiyamaKK | lld:pubmed |
| pubmed-article:6546688 | pubmed:author | pubmed-author:RoeskeW RWR | lld:pubmed |
| pubmed-article:6546688 | pubmed:author | pubmed-author:WatsonMM | lld:pubmed |
| pubmed-article:6546688 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6546688 | pubmed:day | 29 | lld:pubmed |
| pubmed-article:6546688 | pubmed:volume | 119 | lld:pubmed |
| pubmed-article:6546688 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6546688 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6546688 | pubmed:pagination | 289-97 | lld:pubmed |
| pubmed-article:6546688 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:meshHeading | pubmed-meshheading:6546688-... | lld:pubmed |
| pubmed-article:6546688 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6546688 | pubmed:articleTitle | High-affinity [3H]pirenzepine binding to putative M1 muscarinic sites in the neuroblastoma x glioma hybrid cell line (NG 108-15). | lld:pubmed |
| pubmed-article:6546688 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6546688 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6546688 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6546688 | lld:pubmed |
